Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.
Open Orphan plc has changed its name to hVIVO plc (Ticker: HVO)
Watch hVIVO’s Capital Markets Day 2022 presentation here.
At hVIVO, we play an important role in improving global health by supporting the clinical development of medicinal products, especially infectious and respiratory disease products, through human challenge trials. As a growing organization, we recognise the importance of continually improving our governance and prioritising social and environmental concerns in all our work.
We are committed to operating as a responsible business; and as part of this commitment, we are currently assessing the Company’s environmental, social and governance protocols and policies. hVIVO has established a cross business working group, called the ESG Group, which focuses on identifying risks and opportunities related to climate change and other social and governance topics. Yamin ‘Mo’ Khan leads the ESG Group and report directly to the Audit and Risk Committee. The ESG Group consists of representatives from various areas of our business and report to the to Audit and Risk Committee, which is responsible for reviewing the Company’s ESG reporting and recommending it to the Board.
We operate our trials in the highest quality safety, regulatory and ethical environment. We are committed to honesty, transparency and quality which is embedded in our Clinical Governance Policy and Business Code of Ethics.
Infectious diseases are a significant burden to global health, and hVIVO plays an important role in helping to bring vital vaccines & antivirals to the market faster than otherwise possible, using human clinical trials.
We place volunteers and patients at the heart of our business and carefully safeguard their wellbeing in clinical research and data protection, and ensure that their feedback is heard so that we can continually improve our processes.
Our employees are the key to our success; in line with our Diversity & Equal Opportunities Policy, we are focussed on building a strong corporate culture, with diversity and equality at the centre.
We are committed to reducing our impact on the environment; as part of our Environmental Policy, we ensure all energy consumption is monitored and are working towards implementing measurable metrics and targets to help minimise our carbon footprint.
We believe in giving back to our community and those in need. To achieve this goal, we have implemented numerous new initiatives hVIVO’s Volunteering Policy and work towards the implementation of new initiatives such as our Charitable Donations Policy and Community Engagement Programme.
Yamin 'Mo' Khan
CEO & Head of the ESG Group
“Our ESG policies have been developed in‐line with hVIVO’s core values to ensure we engage in ethical and compliant business practices, from the execution of our clinical trials to our interactions with colleagues, volunteers, clients, vendors, investors and all other stakeholders.
In the workplace, we aim to build and maintain a diverse and inclusive environment to allow our talented team to thrive.
We recognise our responsibility to reduce our impact on the environment whenever possible and strive to minimise our carbon footprint through energy efficient practices, sourcing from local and sustainable suppliers, and reducing waste.”